MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Samples
2.2. Nucleic Acid Isolation
2.3. Quantification of miRNA Expression Levels
2.4. Immunohistochemistry
2.5. Statistical Analysis
3. Results
3.1. Prevalence of MiR-199b Deregulation and Its Association with Molecular and Clinical Parameters in Early-Stage CRC Patients
3.2. Clinical Significance of MiR-199b Downregulation in Early-Stage Colorectal Cancer
3.3. MiR-199b Correlated with SET but Showed an Independent Prognostic Value
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [Green Version]
- Lermos, C.; Sack, U.; Schmid, F.; Juneja, M.; Stein, U. Anti-metastatic treatment in colorectal cancer: Targeting signaling pathways. Curr. Pharm. Des. 2013, 19, 841–863. [Google Scholar] [CrossRef]
- Gill, S.; Blackstock, A.W.; Goldberg, R.M. Colorectal cancer. Mayo Clin. Proc. 2007, 82, 114–129. [Google Scholar] [CrossRef]
- Lombardi, L.; Morelli, F.; Cinieri, S.; Santini, D.; Silvestris, N.; Fazio, N.; Orlando, L.; Tonini, G.; Colucci, G.; Maiello, E. Adjuvant colon cancer chemotherapy: Where we are and where we’ll go. Cancer Treat. Rev. 2010, 36, S34–S41. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fedewa, S.A.; Ahnen, D.J.; Meester, R.G.S.; Barzi, A.; Jemal, A. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 177–193. [Google Scholar] [CrossRef] [PubMed]
- Engstrand, J.; Nilsson, H.; Strömberg, C.; Jonas, E.; Freedman, J. Colorectal Cancer Liver Metastases—A Population-Based Study on Incidence, Management and Survival. BMC Cancer 2018, 18, 78. [Google Scholar] [CrossRef] [PubMed]
- Ewing, I.; Hurley, J.J.; Josephides, E.; Millar, A. The molecular genetics of colorectal cancer. Frontline Gastroenterol. 2014, 5, 26–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kong, Y.W.; Ferland-McCollough, D.; Jackson, T.J.; Bushell, M. MicroRNAs in cancer management. Lancet Oncol. 2012, 13, e249–e258. [Google Scholar] [CrossRef]
- Favreau, A.J.; Cross, E.L.; Sathyanarayana, P. miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. Am. J. Hematol. 2012, 87, 442–446. [Google Scholar] [CrossRef] [Green Version]
- Torres, A.; Torres, K.; Pesci, A.; Ceccaroni, M.; Paszkowski, T.; Cassandrini, P.; Zamboni, G.; Maciejewski, R. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012, 12, 369. [Google Scholar] [CrossRef] [Green Version]
- Fang, C.; Zhao, Y.; Guo, B. MiR-199b-5p targets HER2 in breast cancer cells. J. Cell Biochem. 2013, 114, 1457–1463. [Google Scholar] [CrossRef] [PubMed]
- Shang, W.; Chen, X.; Nie, L.; Xu, M.; Chen, N.; Zeng, H.; Zhou, Q. MiR199b suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in prostate cancer cells. Int. J. Mol. Sci. 2013, 14, 8422–8436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, M.X.; Siu, M.K.; Liu, S.S.; Yam, J.W.; Ngan, H.Y.; Chan, D.W. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5, 944–958. [Google Scholar] [CrossRef] [Green Version]
- Joshi, D.; Chandrakala, S.; Korgaonkar, S.; Ghosh, K.; Vundinti, B.R. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene 2014, 542, 109–112. [Google Scholar] [CrossRef] [PubMed]
- Sousa, L.O.; Sobral, L.M.; Matsumoto, C.S.; Saggioro, F.P.; López, R.V.; Panepucci, R.A.; Curti, C.; Silva, W.A., Jr.; Greene, L.J.; Leopoldino, A.M. Lymph node or perineural invasion is associated with low miR-15a, miR-34c and miR-199b levels in head and neck squamous cell carcinoma. BBA Clin. 2016, 6, 159–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, S.J.; Liu, F.Y.; Zhang, A.H.; Liang, H.F.; Wang, Y.; Ma, R.; Jiang, Y.H.; Sun, N.F. MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Br. J. Cancer 2017, 117, 233–244. [Google Scholar] [CrossRef]
- Lai, Y.; Quan, J.; Lin, C.; Li, H.; Hu, J.; Chen, P.; Xu, J.; Guan, X.; Xu, W.; Lai, Y.; et al. miR-199b-5p serves as a tumor suppressor in renal cell carcinoma. Exp. Ther. Med. 2018, 16, 436–444. [Google Scholar]
- Wu, A.; Chen, Y.; Liu, Y.; Lai, Y.; Liu, D. miR-199b-5p inhibits triple negative breast cancer cell proliferation, migration and invasion by targeting DDR1. Oncol. Lett. 2018, 16, 4889–4896. [Google Scholar] [CrossRef] [Green Version]
- Li, G.L.; Yuan, J.H.; Zhuang, G.D.; Wu, D.Q. miR-199b exerts tumor suppressive functions in hepatocellular carcinoma by directly targeting JAG1. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 7679–7687. [Google Scholar]
- Shen, Z.L.; Wang, B.; Jiang, K.W.; Ye, C.X.; Cheng, C.; Yan, Y.C.; Zhang, J.Z.; Yang, Y.; Gao, Z.D.; Ye, Y.J.; et al. Downregulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling. Oncotarget 2016, 7, 35092–35105. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.Y.; Zhi, Z.; Wang, L.; Zhao, Y.Y.; Deng, M.; Liu, Y.H.; Qin, Y.; Tian, M.M.; Liu, Y.; Shen, T.; et al. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling. J. Pathol. 2019, 248, 103–115. [Google Scholar] [CrossRef] [PubMed]
- Chao, A.; Tsai, C.L.; Wei, P.C.; Hsueh, S.; Chao, A.S.; Wang, C.J.; Tsai, C.N.; Lee, Y.S.; Wang, T.H.; Lai, C.H. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett. 2010, 291, 99–107. [Google Scholar] [CrossRef]
- Cristóbal, I.; Caramés, C.; Rincón, R.; Manso, R.; Madoz-Gúrpide, J.; Torrejón, B.; González-Alonso, P.; Rojo, F.; García-Foncillas, J. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget 2017, 8, 40169–40180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baek, D.W.; Kim, G.; Kang, B.W.; Kim, H.J.; Park, S.Y.; Park, J.S.; Choi, G.S.; Kang, M.K.; Hur, K.; Kim, J.G. High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer. J. Cancer Res. Clin. Oncol. 2020, 146, 105–115. [Google Scholar] [CrossRef] [PubMed]
- Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
- McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clarck, G.M. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 2005, 23, 9067–9072. [Google Scholar] [CrossRef] [Green Version]
- Jin, H.; Jang, Y.; Cheng, N.; Li, Q.; Cui, P.F.; Zhou, Z.W.; Jiang, H.L.; Cho, M.H.; Westover, K.D.; Tan, Q.Y.; et al. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. J. Exp. Clin. Cancer Res. 2019, 38, 165. [Google Scholar] [CrossRef]
- Wang, C.; Song, B.; Song, W.; Liu, J.; Sun, A.; Wu, D.; Yu, H.; Lian, J.; Chen, L.; Han, J. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J. Gastroenterol. Hepatol. 2011, 26, 1630–1637. [Google Scholar] [CrossRef]
- Favreau, A.J.; McGlauflin, R.E.; Duarte, C.W.; Sathyanarayana, P. miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications. Exp. Hematol. Oncol. 2016, 5, 4. [Google Scholar] [CrossRef] [Green Version]
- Fang, C.; Wang, F.B.; Li, Y.; Zeng, X.T. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients. Biomed. Pharmacother. 2016, 84, 1189–1193. [Google Scholar] [CrossRef]
- Sakaguchi, T.; Yoshino, H.; Yonemori, M.; Miyamoto, K.; Sugita, S.; Matsushita, R.; Itesako, T.; Tatarano, S.; Nakagawa, M.; Enokida, H. Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. Br. J. Cancer 2017, 116, 1077–1087. [Google Scholar] [CrossRef] [PubMed]
- Cristóbal, I.; Rubio, J.; Santos, A.; Torrejón, B.; Caramés, C.; Imedio, L.; Mariblanca, S.; Luque, M.; Sanz-Alvarez, M.; Zazo, S.; et al. MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. Cancers 2020, 12, 1655. [Google Scholar] [CrossRef] [PubMed]
- Cristóbal, I.; Torrejón, B.; Rubio, J.; Santos, A.; Pedregal, M.; Caramés, C.; Zazo, S.; Luque, M.; Sanz-Alvarez, M.; Madoz-Gúrpide, J.; et al. Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer. J. Clin. Med. 2019, 8, 346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, W.J.; Xiong, L.; Yang, L.; Yang, L.J.; Li, L.; Huang, L.; Liang, X.Q.; Xue, J.; Tan, B.Z. Long Non-Coding RNA LINC01783 Promotes the Progression of Cervical Cancer by Sponging miR-199b-5p to Mediate GBP1 Expression. Cancer Manag. Res. 2020, 12, 363–373. [Google Scholar] [CrossRef] [Green Version]
- Peng, W.; He, D.; Shan, B.; Wang, J.; Shi, W.; Zhao, W.; Peng, Z.; Luo, Q.; Duan, M.; Li, B.; et al. LINC81507 act as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1/STAT3 pathway. Cell Death Dis. 2019, 10, 1–15. [Google Scholar] [CrossRef]
- DAS, M.K.; Andreassen, R.; Haugen, T.B.; Furu, K. Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. Cancer Genom. Proteom. 2016, 13, 63–68. [Google Scholar]
Parameters | No. Cases | High MiR-199b (%) | Low MiR-199b (%) | p | ||
---|---|---|---|---|---|---|
MiR-199b | 171 | 134 | (78.4) | 37 | (21.6) | |
Sex | 171 | 134 | 37 | 0.478 | ||
Male | 107 | 82 | (76.6) | 25 | (23.4) | |
Female | 64 | 52 | (81.2) | 12 | (18.8) | |
Age | 168 | 132 | 36 | 0.616 | ||
<70 | 62 | 50 | (81.9) | 12 | (18.1) | |
≥70 | 106 | 82 | (77.4) | 24 | (22.6) | |
ECOG | 168 | 132 | 36 | 0.045 | ||
0–1 | 157 | 126 | (80.3) | 31 | (19.7) | |
2–3 | 11 | 6 | (54.1) | 5 | (45.9) | |
T | 171 | 134 | 37 | 0.333 | ||
1 | 3 | 3 | (100) | 0 | (14.3) | |
2 | 40 | 34 | (85) | 6 | (15) | |
3 | 108 | 80 | (74.1) | 28 | (25.9) | |
4 | 19 | 16 | (84.2) | 3 | (16.8) | |
x | 1 | 1 | (100) | 0 | (0) | |
n | 171 | 134 | 37 | 0.848 | ||
0 | 82 | 64 | (78) | 18 | (22) | |
1 | 46 | 37 | (80.4) | 9 | (19.6) | |
2 | 30 | 24 | (80) | 6 | (20) | |
x | 13 | 9 | (69.2) | 4 | (30.8) | |
Stage | 171 | 134 | 37 | 0.924 | ||
I–II | 82 | 64 | (78) | 18 | (22) | |
III | 89 | 70 | (78.7) | 19 | (21.3) | |
Site of primary tumor | 166 | 131 | 35 | 0.643 | ||
Colon | 123 | 96 | (78) | 27 | (22) | |
Rectum | 43 | 35 | (81.4) | 8 | (18.6) | |
Metachronous metastasis | 171 | 134 | 37 | 0.825 | ||
No | 127 | 99 | (78) | 28 | (22) | |
Yes | 44 | 35 | (79.5) | 9 | (20.5) |
No. Cases | High MiR-199b (%) | Low MiR-199b (%) | p | |||
---|---|---|---|---|---|---|
SET | 144 | 112 | 32 | 0.004 | ||
Low | 122 | 100 | (82) | 22 | (18) | |
High | 22 | 12 | (54.5) | 10 | (45.5) |
Univariate OS Analysis | Multivariate OS Cox Analysis | |||||||
---|---|---|---|---|---|---|---|---|
Parameters | HR | 95% CI | p | HR | 95% CI | p | ||
Lower | Upper | Lower | Upper | |||||
Gender | 0.576 | |||||||
Male | 1.000 | |||||||
Female | 0.862 | 0.512 to 1.451 | ||||||
Age | 0.011 | 0.022 | ||||||
<70 | 1.000 | 1.000 | ||||||
>70 | 2.147 | 1.189 to 3.380 | 2.193 | 1.120 to 4.293 | ||||
Stage | 0.015 | 0.184 | ||||||
I–II | 1.000 | 1.000 | ||||||
III | 1.934 | 1.137 to 3.287 | 1.661 | 0.786 to 3.512 | ||||
ECOG | <0.001 | <0.001 | ||||||
0–1 | 1.000 | 1.000 | ||||||
2–3 | 2.274 | 1.588 to 3.256 | 2.069 | 1.388 to 3.085 | ||||
T | 0.224 | |||||||
1–2 | 1.000 | |||||||
>2 | 1.217 | 0.887 to 1.670 | ||||||
n | 0.046 | 0.447 | ||||||
0–1 | 1.000 | 1.000 | ||||||
2–x | 1.727 | 1.009 to 2.954 | 1.297 | 0.663 to 2.536 | ||||
SET | 0.023 | 0.082 | ||||||
Low | 1.000 | 1.000 | ||||||
High | 2.121 | 1.112 to 4.046 | 1.843 | 0.926 to 3.666 | ||||
MiR-199b | 0.001 | 0.002 | ||||||
Low | 1.000 | 1.000 | ||||||
High | 0.399 | 0.234 to 0.678 | 0.378 | 0.207 to 0.693 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cristóbal, I.; Rubio, J.; Torrejón, B.; Santos, A.; Caramés, C.; Luque, M.; Sanz-Álvarez, M.; Alonso, R.; Zazo, S.; Madoz-Gúrpide, J.; et al. MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer. J. Clin. Med. 2020, 9, 2419. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9082419
Cristóbal I, Rubio J, Torrejón B, Santos A, Caramés C, Luque M, Sanz-Álvarez M, Alonso R, Zazo S, Madoz-Gúrpide J, et al. MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer. Journal of Clinical Medicine. 2020; 9(8):2419. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9082419
Chicago/Turabian StyleCristóbal, Ion, Jaime Rubio, Blanca Torrejón, Andrea Santos, Cristina Caramés, Melani Luque, Marta Sanz-Álvarez, Ruth Alonso, Sandra Zazo, Juan Madoz-Gúrpide, and et al. 2020. "MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer" Journal of Clinical Medicine 9, no. 8: 2419. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9082419